Pharmacological and clinical profiles of new soluble basal insulin analogue, Insulin Detemir (Levemir).
Katayama
Yasuyuki
Y
ykya@novonordisk.com
Inoue
Akihiro
A
Horigome
Hiroaki
H
D000818:Animals; D001682:Biological Availability; D002986:Clinical Trials as Topic; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D006801:Humans; D007279:Injections, Subcutaneous; D007328:Insulin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000378:metabolism / Q000493:pharmacokinetics / Q000494:pharmacology; D000069057:Insulin Detemir; D049528:Insulin, Long-Acting; D011485:Protein Binding; D017526:Receptor, IGF Type 1 / Q000378:metabolism; D011972:Receptor, Insulin / Q000378:metabolism; D012995:Solubility
D007328:Insulin; D049528:Insulin, Long-Acting; D000069057:Insulin Detemir; D017526:Receptor, IGF Type 1; D011972:Receptor, Insulin